Skip header and navigation

18 records – page 1 of 1.

Health Canada consultation on Canadian drugs and substances strategy

https://policybase.cma.ca/en/permalink/policy14017
Date
2018-Dec-04
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
, based on the needs of each patient? 4 Policy makers must recognize that prescription opioids
  1 document  

Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model

https://policybase.cma.ca/en/permalink/policy13932
Date
2018-Oct-31
Topics
Population health/ health equity/ public health
  1 document  

Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

https://policybase.cma.ca/en/permalink/policy13931
Date
2018-Aug-30
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
alone, overdose deaths related to opioids increased by 45 per cent in 2017, with more than three people
  1 document  

Health Canada consultation on regulatory amendments regarding tramadol

https://policybase.cma.ca/en/permalink/policy13927
Date
2018-Aug-14
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
for Health Information reports that tramadol is one of six opioids accounting for 96% of all opioid
  1 document  

Health Canada consultation on restriction of marketing and advertising of opioids

https://policybase.cma.ca/en/permalink/policy13921
Date
2018-Jul-18
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
AND ADVERTISING OF OPIOIDS July 18, 2018
  1 document  

Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/en/permalink/policy13734
Date
2017-Nov-7
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
-2016-e.pdf (accessed: 2017 Nov 7). 14 Canadian Medical Association. Harms Associated with Opioids
  1 document  

Opioid overdose prevention supplies available in publicly accessible locations

https://policybase.cma.ca/en/permalink/policy13703
Date
2017-Aug-23
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
Policy Type
Policy resolution
Date
2017-Aug-23
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports making naloxone and other opioid overdose prevention supplies available in publicly accessible locations.
Less detail

CMA submission to the study of Bill C-37

https://policybase.cma.ca/en/permalink/policy13617
Date
2017-April-06
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
  1 document  

Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada

https://policybase.cma.ca/en/permalink/policy13936
Date
2016-Oct-18
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Population health/ health equity/ public health
Health care and patient safety
with the management of acute and chronic pain. Policy makers must recognize that prescription opioids
  1 document  

Canadian guideline for safe and effective use of opioids for chronic pain

https://policybase.cma.ca/en/permalink/policy11901
Date
2016-Aug-24
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association recommends that the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain include consideration of pharmacokinetic and pharmacodynamic factors specific to older adults.
Policy Type
Policy resolution
Date
2016-Aug-24
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association recommends that the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain include consideration of pharmacokinetic and pharmacodynamic factors specific to older adults.
Less detail

Consultation on the prescription drug list: Naloxone

https://policybase.cma.ca/en/permalink/policy11847
Date
2016-Mar-17
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
standards for health and health care. The harms associated with opioids, which include prescription
  1 document  

Harms associated with opioids and other psychoactive prescription drugs

https://policybase.cma.ca/en/permalink/policy11535
Date
2015-May-30
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
(www.cma.ca). CMA POLICY HARMS ASSOCIATED WITH OPIOIDS AND OTHER PSYCHOACTIVE PRESCRIPTION DRUGS
  1 document  

Tamper Resistance under the Controlled Drugs and Substances Act

https://policybase.cma.ca/en/permalink/policy11295
Date
2014-Aug-26
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
. However, at the same time, there was a rise in the use of heroin and other opioids which did not have
  1 document  

Opioid overdose prevention tools and services

https://policybase.cma.ca/en/permalink/policy11248
Date
2014-Aug-20
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports community-based programs that offer access to opioid overdose prevention tools and services.
Policy Type
Policy resolution
Date
2014-Aug-20
Topics
Health care and patient safety
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
Resolution
The Canadian Medical Association supports community-based programs that offer access to opioid overdose prevention tools and services.
Less detail

Proposed amendments to the marihuana for medical purposes regulations

https://policybase.cma.ca/en/permalink/policy11293
Date
2014-Jul-11
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
to patients and the possibility for misuse or abuse of medications, particularly opioids and other
  1 document  

CMA's Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety

https://policybase.cma.ca/en/permalink/policy11125
Date
2014-Mar-26
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
consumption of prescription opioids in the world, after the United States. The misuse and abuse
  1 document  

Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/en/permalink/policy11114
Date
2014-Mar-17
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
and abuse of controlled psychoactive prescription medicines, notably opioids such as oxycodone, fentanyl
  1 document  

The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/en/permalink/policy11035
Date
2013-Nov-27
Topics
Pharmaceuticals/ prescribing/ cannabis/ marijuana/ drugs
and abuse of controlled psychoactive prescription medications, notably opioids such as oxycodone, fentanyl
  1 document  

18 records – page 1 of 1.